SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — May 29, 2012
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: May 29, 2012 · CIK: 0001213037 · Accession: 0001104659-12-040233
AI Filing Summary & Sentiment
File numbers found in text: 333-180810
Letter
Re:
AEGIS CAPITAL CORP. 810 7TH Avenue New York, New York 10019
May 25, 2012
VIA EDGAR AND TELECOPY
Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549
Trovagene, Inc. (the “Company”)
File No. 333-180810
Registration Statement on Form S-1
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, we, as representatives of the several underwriters, hereby request acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 5:00 p.m., Washington D.C. time, on Tuesday, May 29, 2012, or as soon thereafter as practicable.
The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:
(i)
Date of preliminary prospectus: May 8, 2012, as amended on May 18, 2012, May 22, 2012, May 23, 2012 and May 25, 2012
(ii)
Dates of distribution: May 8, 2012 — May 29, 2012
(iii)
Number of prospective underwriters and dealers to whom the preliminary prospectus was furnished: 4
(iv)
Number of prospectuses so distributed: 600
The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Very truly yours,
AEGIS CAPITAL CORP.
Show Raw Text
CORRESP 1 filename1.htm AEGIS CAPITAL CORP. 810 7TH Avenue New York, New York 10019 May 25, 2012 VIA EDGAR AND TELECOPY Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Trovagene, Inc. (the “Company”) File No. 333-180810 Registration Statement on Form S-1 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, we, as representatives of the several underwriters, hereby request acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 5:00 p.m., Washington D.C. time, on Tuesday, May 29, 2012, or as soon thereafter as practicable. The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933: (i) Date of preliminary prospectus: May 8, 2012, as amended on May 18, 2012, May 22, 2012, May 23, 2012 and May 25, 2012 (ii) Dates of distribution: May 8, 2012 — May 29, 2012 (iii) Number of prospective underwriters and dealers to whom the preliminary prospectus was furnished: 4 (iv) Number of prospectuses so distributed: 600 The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue. Very truly yours, AEGIS CAPITAL CORP. By: /s/ Kevin C. McKenna Name: Kevin C. McKenna Title: Chief Compliance Officer